Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CCM
CCM logo

CCM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.020
Open
4.020
VWAP
3.94
Vol
1.91K
Mkt Cap
17.15M
Low
3.840
Amount
7.54K
EV/EBITDA(TTM)
--
Total Shares
4.34M
EV
1.05B
EV/OCF(TTM)
--
P/S(TTM)
0.19
Concord Medical Services Holdings Ltd is an investment holding company primarily engaged in the provision of comprehensive solutions for cancer medical treatment. The Company operates its business through two segments. The Network segment is engaged in providing enterprise customers with integrated oncology-related solutions, including primarily the supply, management and technical support for medical equipment and software solutions, and providing equipment leasing and comprehensive support services. The Hospital segment is engaged in providing a full spectrum of oncology healthcare services to cancer patients across the entire care continuum through its self-owned cancer hospitals and clinics. The Company mainly conducts its business in the domestic market.
Show More

Events Timeline

(ET)
2024-12-09
06:42:00
Concord Medical: Application for proton therapy equipment registration approved
select
2024-09-16 (ET)
2024-09-16
08:11:22
Concord Medical obtains procurement license for proton equipment
select

News

PRnewswire
9.5
04-29PRnewswire
Concord Medical Files Annual Report for 2025
  • Annual Report Filing: Concord Medical filed its annual report for the fiscal year ending December 31, 2025, with the SEC on April 29, 2026, reflecting the company's commitment to transparency and compliance, ensuring timely access to critical information for investors.
  • Report Access: Shareholders can access the electronic version of the annual report on Concord Medical's investor relations website and the SEC's site, with hard copies available upon request at no charge, demonstrating the company's focus on shareholder service.
  • Healthcare Services Overview: Concord Medical specializes in a full cycle of oncology services, including cancer diagnosis, treatment, education, and prevention, aiming to enhance the quality and accessibility of cancer care through its network of self-owned and partnered hospitals to meet growing market demand.
  • Investment in Technology: The company equips its cancer hospitals with advanced technologies, such as state-of-the-art proton therapy systems, aiming to improve treatment outcomes through innovation, thereby strengthening its competitive position in China's cancer treatment market.
Newsfilter
9.5
04-29Newsfilter
Concord Medical Files Annual Report for 2025
  • Annual Report Filing: Concord Medical filed its annual report for the fiscal year ending December 31, 2025, with the SEC on April 29, 2026, reflecting the company's ongoing commitment to transparency and compliance, ensuring timely access to critical information for investors.
  • Report Access: Shareholders can access the electronic version of the annual report on Concord Medical's investor relations website and the SEC's site, with hard copies available upon request at no charge, demonstrating the company's dedication to shareholder service and information transparency.
  • Healthcare Services Overview: Concord Medical specializes in cancer treatment, research, education, and prevention, offering a full cycle of premium oncology services aimed at improving the quality and accessibility of cancer care through its network of owned and partnered hospitals, addressing the growing market demand.
  • Investment in Technology: The company equips its cancer hospitals with advanced technology, including state-of-the-art proton therapy systems, aiming to enhance treatment outcomes through innovation, thereby strengthening its competitive position in China's oncology healthcare market.
Benzinga
9.5
2025-12-05Benzinga
Ulta Beauty Stock Rises Approximately 6%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Ulta Beauty Earnings Report: Ulta Beauty, Inc. reported third-quarter earnings of $5.14 per share, surpassing analyst expectations, and raised its full-year GAAP EPS guidance, leading to a 5.7% increase in share price during pre-market trading.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including Lion Group Holding Ltd (+57.3%), SMX (+42.9%), and Akanda Corp (+30.1%), following positive developments and shareholder approvals.

  • Stocks Experiencing Losses: Sportsman’s Warehouse Holdings Inc. faced an 18.8% drop after disappointing third-quarter results, while Protara Therapeutics Inc. fell 14.3% due to a public offering announcement.

  • Market Overview: The overall market showed mixed results, with some companies like Rubrik, Inc. and Zumiez Inc. reporting strong earnings and positive outlooks, while others like Hewlett Packard Enterprise Co. and Docusign Inc. reported weaker-than-expected results.

PRnewswire
1.0
2025-12-02PRnewswire
Concord Medical to Hold 2025 Annual Shareholders Meeting on December 29
  • Meeting Schedule: Concord Medical will hold its annual shareholders meeting on December 29, 2025, at 10:00 a.m. in Beijing, allowing shareholders to discuss company affairs with management without any proposals for approval.
  • Record Date: The shareholder record date is set for December 19, 2025, ensuring that all eligible shareholders can participate in the meeting and stay informed about the company's latest developments.
  • Financial Report Disclosure: The company has filed its Form 20-F with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2024, which includes audited financial statements, thereby enhancing transparency and investor confidence.
  • Business Background: Concord Medical focuses on providing a full cycle of oncology services, including diagnosis, treatment, education, and prevention, striving to improve the quality and accessibility of cancer care across China.
NASDAQ.COM
9.5
2025-09-26NASDAQ.COM
Concord Medical Services Holdings Ltd. Reports Reduced Losses in H1
  • Financial Performance: Concord Medical Services Holdings Ltd. reported a loss of RMB27.135 million for the first half of the year, an improvement from a loss of RMB172.258 million in the same period last year.

  • Revenue Decline: The company's revenue decreased by 8.3% to RMB200.615 million, down from RMB218.810 million in the previous year.

PRnewswire
9.5
2025-09-26PRnewswire
Concord Medical Reports Financial Results for the First Half of 2025
  • Financial Performance: Concord Medical reported total net revenues of RMB200.6 million (US$28.0 million) for the first half of 2025, an 8.3% decrease from the previous year, with a gross loss of RMB4.3 million (US$0.6 million) compared to RMB41.6 million in the same period last year.

  • Proton Therapy Advancements: The company highlighted the successful implementation of proton therapy at Guangzhou Concord Cancer Hospital, showing significant tumor regression in patients and improved outcomes for challenging cancers while minimizing side effects.

Valuation Metrics

The current forward P/E ratio for Concord Medical Services Holdings Ltd (CCM.N) is 0.00, compared to its 5-year average forward P/E of -35.23. For a more detailed relative valuation and DCF analysis to assess Concord Medical Services Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-35.23
Current PE
0.00
Overvalued PE
-16.65
Undervalued PE
-53.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
36.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
107.75
Undervalued EV/EBITDA
-35.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.30
Current PS
0.00
Overvalued PS
2.18
Undervalued PS
0.41

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

create swing trade setup
Intellectia · 358 candidates
Price: $1.00 - $5.00List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA5, PriceBelowMA10Week Price Change Pct: $-10.00 - $10.00Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
TCRT logo
TCRT
Alaunos Therapeutics Inc
7.60M
OSTX logo
OSTX
OS Therapies Inc
53.17M
NNOX logo
NNOX
Nano-X Imaging Ltd
169.34M
FLNT logo
FLNT
Fluent Inc
107.58M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
685.30M
MRT logo
MRT
Marti Technologies Inc
175.91M

Whales Holding CCM

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Concord Medical Services Holdings Ltd (CCM) stock price today?

The current price of CCM is 3.95 USD — it has increased 0

What is Concord Medical Services Holdings Ltd (CCM)'s business?

Concord Medical Services Holdings Ltd is an investment holding company primarily engaged in the provision of comprehensive solutions for cancer medical treatment. The Company operates its business through two segments. The Network segment is engaged in providing enterprise customers with integrated oncology-related solutions, including primarily the supply, management and technical support for medical equipment and software solutions, and providing equipment leasing and comprehensive support services. The Hospital segment is engaged in providing a full spectrum of oncology healthcare services to cancer patients across the entire care continuum through its self-owned cancer hospitals and clinics. The Company mainly conducts its business in the domestic market.

What is the price predicton of CCM Stock?

Wall Street analysts forecast CCM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Concord Medical Services Holdings Ltd (CCM)'s revenue for the last quarter?

Concord Medical Services Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Concord Medical Services Holdings Ltd (CCM)'s earnings per share (EPS) for the last quarter?

Concord Medical Services Holdings Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Concord Medical Services Holdings Ltd (CCM). have?

Concord Medical Services Holdings Ltd (CCM) has 595 emplpoyees as of May 04 2026.

What is Concord Medical Services Holdings Ltd (CCM) market cap?

Today CCM has the market capitalization of 17.15M USD.